In Memoriam
Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective
Economic Burden of Patients with Anemia in Selected Diseases
Impact of Computer-Generated Personalized Goals on Cholesterol Lowering
An Economic Evaluation of Triptan Products for Migraine
A Comparison of Self-Selectivity Corrections in Economic Evaluations and Outcomes Research
USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM) TECHNIQUE IN OUTCOMES RESEARCH
IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES
METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS
UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL
ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME
COSTS OF CARDIOVASCULAR DISEASE
A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE
DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE
MAPPING FROM DISEASE SPECIFIC MEASURES TO UTILITY
QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE
A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS
COST AND QUALITY OF LIFE OF HEMOPHILIA
COST DRIVERS IN MULTIPLE MYELOMA TREATMENT—A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW
OVERACTIVE BLADDER IN MALES
CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH OVERACTIVE BLADDER
IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA
PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING
PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS
PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY—WHAT DO THE PATIENTS WANT?
TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES FOR 10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS
DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A
CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG SCHIZOPHRENIA OUTPATIENTS IN EUROPE
ESTIMATING QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS ORTOXICITY USING A MULTIVARIATE FAILURE TIME REGRESSION MODEL
DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)
TESTING THE CROSS-WALK
“FAMIDIAL STUDY”
VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY
THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A SYNTHESIS OF THE RESULTS OF 1 5 RANDOMISED CONTROLLED TRIALS
PREDICTING THE COST-EFFECTIVENESS OFTHEABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS
HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE MANAGEMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM
ECONOMIC ANALYSIS OF THE STRATEGY STUDY
TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY
EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION
ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER TRANSPLANT RECIPIENTS
PATIENT CHARACTERICS, GLYCEMIC CONTROL,ANDTHE USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES
CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)—6-MONTH RESULTS OF A CANADIAN AS STUDY
IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN
QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS
ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY
COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE-2 DIABETES
COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF PARKINSONISM
PHARMACOECONONOMIC EVALUATION OF SEDATION WITH REMIFENTANIL/PROPOFOLVERSUS MIDAZOLAM/FENTANYL IN THE INTENSIVE CARE UNIT
VALIDATION OF DIAGNOSTIC PROCEDURES IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS IN DAILY CLINICAL PRACTICE
EARLY GLYCEMIC CONTROL IMPROVES HEALTH AND ECONOMIC BENEFITS IN TYPE 2 DIABETES
META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING RANDOMIZED CONTROLLED ADHD TRIALS
A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)
ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA
PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES
THE PHARMACOGENOMICS BIAS IN DECISION MODELS
THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION
EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT
PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B
BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE
PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT)
COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE
COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMALAMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK
LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION
COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY
COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK
HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER
DETERMINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE FOR THE ESPRINT-15 QUESTIONNAIRE FOR PATIENTS WITH ALLERGIC RINHITIS
ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS WITH ALLERGY
DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING SPECIFIC IMMUNO-THERAPY
COSTS AND EFFECTS OF CELECOXIB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS IN THE NETHERLANDS
METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM HIP RESURFACING (BHR)) IN YOUNG PATIENTS WITH SEVERE HIP DAMAGE—A COST UTILITY ANALYSIS
PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE
OSTEOARTHRITIS
OSTEOARTHRITIS
GASTROINTESTINAL (GI) EVENTS, MEDICATION USE AND HEALTH CARE COSTS FOR NEW USERS OF CYCLOOXYGENASE (COX)-2 INHIBITORS AND NONSELECTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP
COST COMPARISON OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS NSAIDS PLUS PROTON PUMP INHIBITORS IN THE TREATMENT OF OSTEOARTHRITIS IN THE NETHERLANDS
A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE
VALIDITY STUDIES AND SATISFACTION THRESHOLD OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)
IMPROVEMENT IN HEALTH UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ADALIMUMAB (HUMIRA®)
THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG
EVALUATION OF ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA USING NATIONAL CLAIMS DATA
TARGETED ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA
POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS
BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY
PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS
CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONGSTANDING, SEVERE RHEUMATOID ARTHRITIS (RA)—RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
COMPARISON OF TREATMENT WITH BUDESONIDE/FORMOTEROL (BUD/FM) PLUS BUD/FM PRN AS SINGLE INHALER TREATMENT VERSUS REGULAR BUD AND FM PLUS FM PRN AS MONOPRODUCTS IN PATIENTS WITH ASTHMA IN GREECE
FLUTICASONE PROPIONATE/SALMETEROL COMBINATION IMPROVES HEALTH OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH POORLY CONTROLLED ASTHMA IN IRELAND
ASTHMA CONTROL IN SPAIN. DOES TREATMENT PROFILE AND SEASON MATTER?
THE COST OF ASTHMA EXACERBATIONS OF DIFFERENT SEVERITY LEVELS
IMPACT OF MONTELUKAST THERAPY ON ASTHMA-RELATED HEALTH CARE RESOURCES USE IN MILD TO MODERATE ASTHMATIC PATIENTS WITH SEASONAL ALLERGIC RHINITIS IN SPAIN
CLINICAL OUTCOME OF CHRONIC ASTHMA
THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA
ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS
THE SPANISH VERSION OF THE MINI-ASTHMA QUALITY OF LIFE QUESTIONNAIRE
ECONOMIC IMPACT OF ADOPTING PEMETREXED PLUS CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA INTO SCOTTISH CLINICAL PRACTICE
LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY
COST OF CARE AND ECONOMIC IMPACT OF CETUXIMAB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER IN POLISH SETTINGS
POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
COST ANALYSIS OF 3-YEARS FOLLOW-UP OF A TRASTUZUMAB TREATED COHORT
INITIATION OF TRANSDERMAL OPIOID THERAPY IN CANCER PATIENTS WITH MODERATE OR SEVERE MALIGNANT PAIN—TREATMENT PATTERNS AND COSTS IN A GERMAN UNIVERSITY HOSPITAL
COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER
THE COST-EFFECTIVENESS OF POST-OPERATIVE RADIOTHERAPY AFTER BREAST CONSERVATION SURGERY IN STAGEI-II BREAST CANCER IN SWEDEN
ECONOMIC EVALUATION OF BORTEZOMIB IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS IN CANADA
IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER
COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)
COST-EFFECTIVENESS ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) ADMINISTERED ONCE EVERY THREE WEEKS COMPARED TO ONCE EVERY WEEK
PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY APPEARS DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL—INTERIM RESULTS FROM A RANDOMIZED CLINICAL TRIAL (RCT)
THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN FOR THE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING CYTOTOXIC THERAPY IN SCOTLAND
LETROZOLE (FEMARA) IS A COST-EFFECTIVE TREATMENT IN THE EXTENDED ADJUVANT SETTING IN WOMEN WITH EARLY BREAST CANCER
AUSTRALIAN COST-EFFECTIVENESS ANALYSIS OF ANASTROZOLEVSTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL
ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM
TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY
COSTS OF COMMON TREATMENT OPTIONS FOR INDOLENT FOLLICULAR NON-HODGKIN'S LYMPHOMA
ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA IN CANCER—A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM
ESTIMATING THE COST OF INFORMAL CAREGIVING IN LUNG CANCER PATIENTS. THE HABIT STUDY
INFLUENCE OF THE PORTION OF MEDICAL EXPENSE PAID INDIVIDUALLY ON PHYSICIANS' ATTITUDE TOWARDS CANCER TREATEMENT IN JAPAN
CUTANEOUS CANCER TREATMENT AND COSTS IN GERMANY
ECONOMIC ANALYSIS OF BISPHOSPHONATES FROM THE PAYERS PERSPECTIVE IN BRAZIL
DOCUMENTATION OF PHARMACY COST IN THE PREPARATION OF CHEMOTHERAPY INFUSIONS IN ACADEMIC AND COMMUNITY-BASED ONCOLOGY PRACTICES
PER-PATIENT COST OF HOSPITAL CARE FOR ADVANCED BREAST CANCER IN THE UK BASED ON A PATIENT-LEVEL RESOURCE UTILISATION DATASET
COMPARATIVE ANALYSIS OF DRUG COST OF BREAST, CERVICAL AND COLORECTAL CANCER IN HUNGARY
COST EFFECTIVENESS MODEL OF IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES
COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK
COST-UTILITY ANALYSIS OF CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC CANCER
COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCER AFTER ANTHRACYCLINE FAILURE
IMPACT OF HEALTH CARE REFORMS AND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY
ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY
APPLICATION OF AN ALGORITHM FOR DEFINING RETROSPECTIVE COHORTS OF COLORECTAL CANCER (CRC) PATIENTS TREATED WITH DIFFERENT FIRST-LINE CHEMOTHERAPY REGIMENS +/− BEVACIZUMABTO ADMINISTRATIVE CLAIMS DATA
DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE CHEMOTHERAPY +/− BEVACIZUMAB, AND INITIATION OF SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS RECORDS
A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC)
MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT ON THE EVOLUTION OF UTILITY IN REFRACTORY MULTIPLE MYELOMA PATIENTS
CRITICAL APPRAISAL OF SCIENTIFIC POSTERS COMPARING ANEMIA TREATMENTS IN CANCER PATIENTS
HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN PROSTATE CANCER
MULTILINGUAL VALIDATION OF THE FACT-LEUKEMIA IN 7 LANGUAGES
WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN ABNORMAL SCREENING-MAMMOGRAPHY?
VALIDATION OF THE SPANISH VERSION OF THE UCLA PROSTATE CANCER INDEX
QUALITY OF LIFE AND RESOURCE UTILIZATION OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST CANCER
A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY
DEVELOPMENT OF A NEW SCALE TO ASSESS PATIENT PERCEPTIONS OF CANCER-RELATED FATIGUE
ASSESSING QOL IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CHEMOTHERAPY
MONITORING AND SECURING QUALITY IN ONCOLOGICAL CARE—THE 2004 LONGITUDINAL PASQOC® RESULTS
FIBROMYALGIA SYNDROME
FIBROMYALGIA SYNDROME
CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS GLOBAL MANAGEMENT OF FIBROMYALGIA
DIAGNOSIS OF FIBROMYALGIA AND HEALTH CARE RESOURCE USE IN PRIMARY CARE IN THE UK
CROSS-SURVEY OF FRENCH AND PORTUGUESE RHEUMATOLOGISTS GLOBAL MANAGEMENT OF FIBROMYALGIA
CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS
THE COST OF PREMATURITY
ESTIMATING A PREFERENCE-BASED MEASURE OF SOCIAL PARTICIPATION FROM THE HANDICAP SCALE FOR CHILDREN
WHAT METHODS OF ASSESSMENT AND MANAGEMENT OF ELDERLY PEOPLE ARE COST EFFECTIVE
SENIORS' PHARMACEUTICAL EXPENDITURES IN THE CZECH REPUBLIC
GRUMPY OLD MEN OR HAPPY YOUNG WOMEN
QUALITY OF LIFE OF ITALIAN GENERAL POPULATION AGED 40 TO 79 YEARS OLD
LIFESTYLE, PHYSICAL ACTIVITY AND EQ-5D HEALTH STATUS IN A OVER 65 YEARS POPULATION
WITHDRAWN
COST-EFFECTIVENESS STUDY OF ASSISTED REPRODUCTIVE TECHNIQUES IN SPAIN
WORK AND HEALTH CONDITIONS DURING PREGNANCY IN WOMEN OF THE MEXICAN SOCIAL SECURITY INSTITUTE
QUALITY OF LIFE AND HEALTH BEHAVIORS OF VENEZUELAN PHARMACY STUDENTS
ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE PSYCHOSOCIAL SUBSCALE OF THE MENOPAUSE-SPECIFIC QUALIPAUSE INVENTORY (QPI)WITH ITEM RESPONSE THEORY
ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA (ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY SCORE MATCHING TO REDUCE RECRUITMENT BIAS
ECONOMIC IMPLICATION OF HEPATITIS BVIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)
COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
DYNAMIC MODELLING FOR ESTIMATING THE COST-EFFECTIVENESS OF A CHLAMYDIA TRACHOMATIS SCREENING PROGRAM
INFECTIONS CAUSED BY RESISTANT CANDIDA SPECIES
WITHDRAWN
INCREASED MANAGEMENT NEEDS AND CARE COSTS FOR NURSING HOME RESIDENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA
A COST UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A (40KD)VERSUS PEGINTERFERON ALFA-2B (12KD) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN THE UK
ANTIMICROBIAL TREATMENT OF ACUTE OTITIS MEDIA AND ITS PHARMACOECONOMIC ANALYSIS IN SLOVAKIA
A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOME IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL
ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA (ACTIVATED)TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT MODELS
SYSTEMATIC REVIEW ON THE SHARE OF ANTIBIOTIC THERAPY COST IN RELATION OVERALL DIRECTTREAMENT COSTS OF MOST FREQUENT NOSOCOMIAL AND COMMUNITY ACQUIRED INFECTIONS IN ADULTS
IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION
IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION
MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS
COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO AN OPTIMISED THERAPYVS.AN OPTIMISED THERAPY ALONE IN PATIENTS WITH H.I.V./AIDS
DETERMINANTS OF HEALTH CARE COSTS IN AMBULATORY PATIENTS LIVING WITH HIV/AIDS
INCORPORATING COMPLIANCE RATES INTO THE COST OF TREATING HIV/AIDS IN TWO AFRICAN COUNTRIES
STUDY VALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV
SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG HIV PATIENT IN UK
COST-UTILITY ANALYSIS OF A HYPOTHETICAL VACCINATION PROGRAM AMONG THE CURRENTLY TARGETED POPULATION IN THE NETHERLANDS IN CASE OF AN INFLUENZA PANDEMIC
COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK
ADDING A QUADRIVALENT (6, 1 1, 16 & 18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING UK CERVICAL SCREENING PROGRAMME IS POTENTIALLY COST-EFFECTIVE
PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN GERMANY
COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORYTRACT INFECTIONS WITH NONSPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT
COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND LIPOSOMALAMPHOTERICIN B FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN
RESOURCE USE AND COSTS ASSOCIATED WITH THE MANAGEMENT OF PAP III, PAP IIID AND PAP IV IN THE PRE-HPVVACCINE ERA IN GERMANY
ESTIMATED ANNUAL NHS COSTS OF HUMAN PAPILLOMAVIRUS (HPV) RELATED DISEASES IN THE UK
INCIDENCE, PREVALENCE AND COSTS OF TREATING GENITAL WARTS IN THE PRE-HPVVACCINE ERA IN GERMANY, 2005
DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE SATISFACTION WITH TREATMENT WITH MEDICINES (SATMED-Q)
REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST GROUP (SIG)
INTERNATIONAL VARIATION IN CLINICAL INJURY INCIDENCE
THE CONTRIBUTION OF PREVENTION AND MEDICAL CARE TO POPULATION HEALTH
A STANDARD SET OF UNIT COSTS FOR GERMANY
AFFORDABLE BOOTSTRAPS? EVALUATING FREEWARE OPTIONS FORANALYZING INCREMENTAL COST EFFECTIVENESS DATA
WITHDRAWN
ESTIMATING COSTS ATTHE FAMILY LEVEL
THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES
A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN THE CONTEXT OF A DECISION ANALYTIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF THE METABOLIC SYNDROME
DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID POPULATION
PHARMACOECONOMIC ASPECTS OF THE ADMINISTRATIVE REFORMS IN PHARMACEUTICAL SECTORS OF REPUBLIC HEALTH DEPARTMENTS IN MONTENEGRO
ECONOMIC IMPACT OF HOSPITAL MALNUTRITION
POPULATION KNOWLEDGE
DIRECT AND INDIRECT COSTS AND EFFECTS IN COST-EFFECTIVENESS ANALYSIS OF PREVENTION
THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY
RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE
PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN COMPUTER-BASED VERSION OF THE SF-36
HOW LONG AGO… ?
INDIRECT COMPARISON (OR COMMON-COMPARATOR) METHODS FOR META-ANALYSIS OF SUMMARY DATA
EVALUATING THE DIFFERENCE BETWEEN AVERAGE WHOLESALE PRICE AND WHOLESALE ACQUISITION COST FOR PHARMACEUTICALS IN THE UNITED STATES
RELATIVE WEIGHTS ASSIGNED TO PHARMACY PROCEDURES
ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE
USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL (PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)
ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT UTILITY INSTRUMENTS—AN EXAMPLE USING IMPUTATION
DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF THE LONDON HANDICAP SCALE
THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)
ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY LIVING SCALE IN ASIAN OLDER ADULTS
COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES
COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM
A COST EFFECTIVENESS MODEL FOR THE EVALUATION OF TOTAL HIP ARTHROPLASTY (THA) AND TOTAL KNEE ARTHROPLASTY (TKA) IN SWEDEN
TRENDS OF DIABETES MELLITUS PREVALENCE AND TREATMENT PATTERNS ASSOCIATED WITH OBESITY IN THE US
PREVALENCE TRENDS IN OVERWEIGHT AND OBESITY AND WEIGHT CONTROL PRACTICES AMONG ADULTS IN THE US
THE ECONOMIC BURDEN OF ADULT OBESITY, WITH SPECIAL REFERENCE TO DRUG CONSUMPTION
COST-OF-ILLNESS ANALYSIS OF JUVENILE OBESITY AND OF CO-MORBIDITYTYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
AN ANALYSIS OF THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS
MODIFICATION OF LIFE STYLE AND OBESITY MANAGEMENT IN PRIMARY CARE
COSTS AND HEALTH CARE CONSUMPTIONS IN THE ABDOMINALLY OBESE POPULATION
VALIDITY OF DATA COLLECTED FROM AN INTERNET-BASED COHORT STUDY
EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)
VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES
THE TIMELY CONSTRUCTION OF AN ARTERIOVENOUS FISTULAE
WITHDRAWN
CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION
BUDGET IMPACT ANALYSIS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY
ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER
DELIVERING TREATMENT EFFECTIVENESS
COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR; A PHARMACO-ECONOMIC ANALYSIS
COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM
COST-EFFECTIVENESS OF MIMPARA AMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
COST ANALYSIS OF RENAL REPLACEMENT THERAPIES IN LATVIA
ASSESSING THE EFFICIENCY OF INTERSTIM® IN FECAL INCONTINENCE (FI) IN THE SPANISH SETTING. A COST-EFFECTIVENESS SIMULATION MODEL
COST-MINIMISATION-ANALYSIS ON THE TREATMENT OF URINARY INCONTINENCE WITH TROSPIUM CHLORIDE IN COMPARISON WITH OXYBUTYNIN IN GERMANY
COST OF ILLNESS OF FEMALE LOWER URINARY TRACT SYMPTOMS (LUTS)
WITHDRAWN
BPH AND IPSS SCORES EVALUATED AFTER 6 MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
BENIGN PROSTATIC HYPERPLASIA
ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN DIALYSIS PATIENTS
EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY WITHIN AN OVERACTIVE BLADDER POPULATION
BENIGN PROSTATE HYPERPLASIA
INDUCED BOTHERSOMENESS IN THE ANALYSIS OF THE IPSS QUESTIONNAIRE
PATIENT SATISFACTION
VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE (KING'S HEALTH QUESTIONNAIRE) IN BRAZILIAN WOMEN WITH URINARY INCONTINENCE
BPH
SPANISH RESEARCH NETWORK ON TRANSPLANTATION
THE IMPACT OF THE OVERACTIVE BLADDER ON QUALITY OF LIFE (SF36) AND UTILITY (EQ5D)
PSYCHOMETRIC VALIDATION OF THE UK ENGLISH INCONTINENCE-SPECIFIC QUALITY OF LIFE MEAURE (I-QOL)
LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER
DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE SYMPTOM CHECKLIST IN URINARY INCONTINENCE
BENIGN PROSTATE HYPERPLASIA
DEVELOPMENT AND PILOT TESTING OF A NEW SCALE SPECIFICALLY MEASURING THE IMPACT OF STRESS URINARY INCONTINENCE (SUI) ON COMMON PHYSICAL ACTIVITIES OF DAILY LIFE
VALIDATION OF THE INTERNATIONAL PROSTATE SYMPTOMS SCORE IN ITALIAN WOMEN WITH LUTS. THE FLOW STUDY
DEVELOPMENT AND TESTING OF A COMPOSITE SCALE TO ASSESS THERAPEUTIC RESPONSE IN STRESS URINARY INCONTINENCE
EVALUATION OF TWO TENSION FREE VAGINAL TAPES WITH URODYNAMICS AND ICIQ-UI SF QUESTIONNAIRE
VALIDATION OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI) IN A BRITISH POPULATION
PATIENT SATISFACTION
COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN HUNGARY
COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80 MG ATORVASTATIN VS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME
A PHARMACO-ECONOMIC EVALUATION OF AGGRESSIVE CHOLESTEROL LOWERING AFTER ACUTE CORONARY SYNDROME IN BELGIUM
HOW MUCH IS THE ACUTE CORONARY SYNDROMES IN-HOSPITAL THERAPY
COST-EFFECTIVENESS OF DRUG ELUTING STENTS FOR STABLE ANGINA
IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE POPULATION
COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND
COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND
THE EFFECT OF ANTICOAGULATION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION-COMPARING EFFICACY AND EFFECTIVENESS
DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE
ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION IN A LARGE COMMERCIALLY INSURED U.S. POPULATION
EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS
THE COST OF ANTICOAGULATION MONITORING SERVICES IN THE UK NATIONAL HEALTH SERVICE
SURVEY OF CURRENT ANTICOAGULANT MONITORING SERVICES IN THE UK—A GENERAL PRACTICE PERSPECTIVE
KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN GERMANY
VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION
WHEN SHOULD PATIENTS BE SWITCHED FROMVKATO NEW TREATMENT
A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES (PRO) USED IN ATRIAL FIBRILLATION
PHARMACOTHERAPY AND OUTCOMES AMONG VETERANS WITH CHRONIC HEART FAILURE (2000-2002)
COST EFFECTIVENESS ANALYSIS OF BISOPROLOL TREATMENT FOR HEART FAILURE
CASE-BASED-COSTING VS. MARKOV-MODELLING—A COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE
ECONOMIC EVALUATION OF VALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING
COST-EFFECTIVENESS ANALYSIS OF ALDOSTERONE BLOCKADE WITH EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION (EPHESUS) IN THE FRENCH CONTEXT
THE ADD-ON TREATMENT WITH METOPROLOL SUCCINATE IN PATIENTS WITH CHRONIC HEART FAILURE (CHF) LEADS TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM—A MODEL APPROACH
COST-EFFECTIVENESS OF CANDESARTAN IN GERMANY FOR PATIENTS WITH CHRONIC HEART FAILURE
COSTS AND OUTCOMES AFTER FIRST HEART FAILURE HOSPITAL ADMISSION
IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS)
USE OF CONTRAST ECHOCARDIOGRAPHY
CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR OUTCOMES IN ACUTE CORONARY SYNDROME PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION
COST-EFFECTIVENESS OF CONTRAST ECHOCARDIOGRAPHY IN THE DIAGNOSIS OF CORONARY ARTERY DISEASE
LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND
A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES
WITHDRAWN
HOSPITALIZATIONS FOR CARDIOVASCULAR EVENTS
USE OF ABCIXIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE
USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
THIENOPYRIDINE THERAPY IN ACUTE CORONARY SYNDROME PATIENTS RESIDING IN GERMANY
THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY OF LIFE AFTER CORONARY STENT IMPLANTATION
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE
PORTUGUESE ACTIVE POPULATION HEALTH RELATED QUALITY OF LIFE RESULTS USING THE SF-6D
RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT
IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES ON TREATMENT OF HYPERCHOLESTEROLEMIA IN DAILY PRACTICE
COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL
THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND
COST-ANALYSIS OF HYPERCHOLESTEROLEMIA TREATMENTS WITHIN THE SLOVAK PHARMACEUTICAL MARKET
ROSUVASTATIN 40MG VERSUS ATORVASTATIN 80MG IN HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLAEMIA
ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
BELGIAN EVALUATION OF SCREENING AND TREATMENT OF HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)
A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003
PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN
IMPACT OF COMPLIANCE AND PERSISTENCE OF TREATMENT WITH VALSARTAN ON HYPERTENSION CLINICAL OUTCOMES
PATIENT PROFILE AND STATINS EFFECTIVENESS IN USUAL CARE
CARDIOVASCULAR RISK CONTROL IN HYPERTENSION AND/OR DYSLIPIDEMIA IN PRIMARY CARE
EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN POLAND
EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES IN POLAND
COST-EFFECTIVENESS OF NEBIVOLOL VERSUS ATENOLOL AND ACE INHIBITOR MONOTHERAPY IN PATIENTS WITH MODERATE HYPERTENSION
COST-EFFECTIVENESS OF INDAPAMIDE IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION
PHARMACO-ECONOMIC ANALYSIS OF VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ)VERSUS CANDESARTAN/HCTZ AND VERSUS TELMISARTAN/HCTZ IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN MEXICO
COST-MINIMIZATION ANALYSIS OF TREATMENT OF MILD-TO-MODERATE HYPERTENSION IN UNITED STATES
THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING HBP MANAGEMENT BY PATIENTS AND PHYSICIANS
LIPID PROFILE IN HYPERTENSIVES WITH AND WITHOUT CARDIOVASCULAR DISEASE
CARDIOVASCULAR DRUG USE IN NIS REGION
HEALTH CARE UTILIZATION OF ANTIHYPERTENSIVE MEDICATION WITHIN THE SLOVAK REPUBLIC
PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR
PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION
FACTORS DETERMINING COMPLIANCE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN DAILY CLINICAL PRACTICE
COST-EFFECTIVENESS OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH PERSISTENT DYSLIPIDEMIA IN AUSTRIAN, SWEDISH AND NORWEGIAN SETTINGS
COST-EFFECTIVENESS OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND PERSISTENTLY LOW HDL-C IN THE UK AND GERMANY
THE COSTS OF METABOLIC SYNDROME
COST-EFFECTIVENESS OF ROSUVASTAT IN COMPARED WITH GENERIC SIMVASTATIN IN THE UK NHS
UTILIZATION PATTERNS OF ASPIRIN AMONG NSAID TREATED SUBJECTS WITH VARYING CARDIOVASCULAR RISK PROFILES IN A HEALTH BENEFITS POPULATION
USE OF PROPENSITY SCORE METHODOLOGY IN CARDIOVASCULAR DEVICE TRIALS
A BUDGET IMPACT MODEL FOR EPLERENONE IN THE TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION
COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI PATIENTS IN POLAND
COST-EFFECTIVENESS ANALYSIS OF THE USE OF ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN THE SECONDARY PREVENTION OF PATIENTS WITH PREVIOUS MYOCARDIAL INFRACTION
COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL INFARCTION HOSPITAL ADMISSION
THE DIRECT COSTS OF SELECTED CARDIOVASCULAR DISEASES IN AUSTRIA
POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION IN LOW RISK PATIENTS. RESULTS WITH A COORDINATED PROGRAM OF CARDIOLOGICAL AND PRIMARY CARE
COST ESTIMATION IN PATIENTS WITH AN ATHEROTROMBOTIC EVENT
DISCRETE EVENT SIMULATION OF LONG-TERM HEALTH BENEFITS AND COST-EFFECTIVENESS OF IMPLANTING DUAL CHAMBERVS. SINGLE CHAMBER VENTRICULAR PACEMAKERS IN ITALY
COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND
COST-EFFECTIVENESS OF ENDOVASCULAR VERSUS CONVENTIONAL ABDOMINAL AORTIC ANEURYSM REPAIR AT ONE YEAR; RESULTS OF A RANDOMIZED TRIAL
SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM
CLINICAL OUTCOME AND COST-EFFECTIVENESS OF DIFFERENT BYPASS MATERIALS IN VASCULAR SURGERY
THE ECONOMIC BURDEN OF EXPERIENCING MAJOR COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION
VITAE THROMBOSIS STUDY
TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENT THROMBOPROPHYLAXIS IN POLAND
COST-EFFECTIVENESS OF AN EXTENDED FOUR-WEEK FONDAPARINUX PROPHYLAXIS REGIMEN FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY
COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS
COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS
HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS RECEIVING VITAMIN K ANTAGONISTS (VKA)
USING EQ-5DTO DERIVE UTILITIES FOR THE QUALITY OF LIFE-ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)
LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD)—A 5 YEAR STUDY
A PROSPECTIVE REAL-LIFE STUDY OF QUALITY OF LIFE IN PATIENTS WITH ACROMEGALY
SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS
CLINICAL OUTCOMES OF RABEPRAZOLE IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE IN REAL-WORLD CLINICAL PRACTICE
COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN
COST-EFFECTIVENESS OF HELICOBACTER PYLORI TESTING FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK
TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN, A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN DATA
THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B (12KD) PLUS RIBAVIRIN VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC) IN A DEVELOPING COUNTRY—BRAZIL
ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH PANTOPRAZOLE IN THE ACUTE AND MAINTENANCE TREATMENT OF REFLUX ESOPHAGITIS IN FINLAND
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) COMPARED TO LAMIVUDINE AS FIRST LINE TREATMENT OF CHRONIC HEPATITIS B (CHB) IN THE UK
ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CD)/ULCERATIVE COLITIS (UC)
COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN
COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND
IBD
THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE—A BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA
THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY
WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS)
MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C VIRUS INFECTION (HCVI) IN BRAZIL
GASTROESOPHAGEAL REFLUX DISEASE (GERD)— PREVALENCE, MANAGEMENT AND COST IN INTERNATIONAL COMPARISON
ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT
META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES
GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE
ECONOMIC VALUATION MODELING FOR ASSESSING BIOTECHNOLOGY/PHARMACEUTICAL DEVELOPMENTAL OPPORTUNITIES
BURDEN OF ILLNESS OF IBS PATIENTS IN THE NETHERLANDS
BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE PAIN SYMPTOMS
ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITY WHILE AT WORK AND IN DAILY ACTIVITIES—RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY
COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A
THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT INHIBITORS
COSTS OF HAEMOPHILIA ASSISTANCE IN ROMANIA
UK COST COMPARISON OF BUCY2 CONDITIONING IN ALLOGENEIC HSCT
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC INSTRUMENT HAEM-A-QOL
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO PROPHYLACTIC REPLACEMENT TREATMENT
DISEASE STATE AND QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)
HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH THEIR TREATMENT
EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE
COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL IN THE UK
RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE
THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC EPILEPSY IN IRELAND
A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY
THE EPIDEMIOLOGY AND MANAGEMENT OF MIGRAINE IN THE UK
IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?
COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO
COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA
THE COSTS OF INFORMAL CARE IN NEUROLOGICAL DISORDERS IN SPAIN
A REVIEW OF THE ECONOMIC EVIDENCE FOR BOTULINUM TOXINS IN SPASTICITY ASSOCIATED WITH STROKE AND CEREBRAL PALSY
A RETROSPECTIVE STUDY OF DRUG TREATMENT PATTERNS AMONGST UK PRIMARY CARE PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) BETWEEN 1ST APRIL 2004 AND 31ST MARCH 2005
IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR)A MEDICAL DEVICE AND PATIENT REGISTRY
USE OF THE SELF-ADMINISTERED NEUROPATHY TOTAL SYMPTOM SCORE—6 (NTSS-6 SA) IN AN INTERNATIONAL STUDY
PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE UPPER EXTREMITIES IN TETRAPLEGIA
THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY
A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE)WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
COST-EFFECTIVENESS OF CONTINUOUS DUODENAL DELIVERY OF LEVODOPA (DUODOPA®) IN PATIENTS WITH SEVERE PARKINSON'S DISEASE
META-ANALYSIS OF CASE SERIES TO PROVIDE INPUTS FORA DISCRETE EVENT SIMULATION OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE
DISEASE SEVERITY AND HEALTH CARE COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
THE COST OF MULTIPLE SCLEROSIS (MS) IN EUROPE
THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF LIFE IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A QUALITATIVE INVESTIGATION OF THE PATIENTS' PERSPECTIVE
SYSTEMATIC REVIEW OF IBANDRONATE FOR POSTMENOPAUSAL OSTEOPOROSIS
CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES
RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN PERSISTENT BISPHOSPHONATE USERS
COST-EFFECTIVENESS OF PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE ORALFACALCIDOL. THE STOP-STUDY
THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS
IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES, PATIENT QUALITY OF LIFE AND TREATMENT COSTS
EVALUATION OF DISTRIBUTION OF HIP REPLACEMENT IN HUNGARY ACCORDING TO GEOGRAPHICAL REGIONS AND AGE GROUPS
CONTENT VALIDATION OF OSTEOPOROSIS TREATMENT PREFERENCE QUESTIONNAIRE
EXTENDING THE BURDEN OF DISEASE PROTOCOL
PERSISTENCE OF DRUG TREATMENT WITH ALENDRONATE AND RISEDRONATE IN PRIMARY CARE PATIENTS
AN INTERNATIONAL COMPARISON OF THE IMPACT OF DOSING FREQUENCY ON COMPLIANCE AND PERSISTENCE WITH BISPHOSPHONATE THERAPY, AMONG POST-MENOPAUSAL WOMEN IN THE US, UK AND GERMANY
HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND AN INADEQUATE RESPONSE TO ANTI-OSTEOPOROSIS MEDICATION
UNDERSTANDING AND ASSESSING TIBIA FRACTURE ON QUALITY OF LIFE; CONCEPTUAL MODEL AND NEW DISEASE SPECIFIC HR-QOL MEASURE
ELICITING AND QUANTIFYING PATIENT PREFERENCES FOR DOSING FREQUENCY
COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH NEUROPATHIC PAIN
THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-RELEASE OPIOIDS FOR THE TREATMENT OF CHRONIC NON-MALIGNANT PAIN
BURDEN OF ILLNESS OF PATIENTS WITH NEUROPATHIC PAIN IN PRIMARY CARE IN THE UK
DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP) MEDICAL MANAGEMENT ACCORDING TO AETIOLOGY
A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICA™(PREGABALIN) VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN
A UK PHARMACOECONOMIC MODEL OF PARENTERAL PARECOXIB VERSUS OPIOID ANALGESIA FOLLOWING MAJOR SURGERY
COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS
THE MOS-SHORT-FORM-12 (SF-12) AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN NEUROPATHIC PAIN (NEP) PATIENTS
HEALTH STATUS AS MEASURED BY PATIENT UTILITY DETERMINATION AMONG PATIENTS WITH PAIN
PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN NEUROPATHIC PAIN (NEP) SYNDROMES
USING THE GENERAL PRACTICE RESEARCH DATABASE TO ESTIMATE THE INCIDENCE, PREVALENCE AND MANAGEMENT OF HYPERHIDROSIS IN THE UK
COST-EFFECTIVENESS ANALYSIS
ECONOMIC EVALUATION OF PIMECROLIMUS, A NEW TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS IN HUNGARY
COST-EFFECTIVENESS MODEL OFALDARA™ (IMIQUIMOD) CREAM, 5% IN SUPERFICIAL BASAL CELL CARCINOMA IN THE NETHERLANDS
WITHDRAWN
COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN GERMANY
EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL GENITAL WARTS (EGW) IN FRANCE
EXAMINATION OF ADHERENCE TO PHARMACOTHERAPY TREATMENT GUIDELINES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION USE
THE RISE OF THE GENERIC DRUG MARKET
PREDICTORS OF HEALTH CARE OUTCOMES AND COSTS RELATED TO MEDICATION USE IN PATIENTS WITH ACNE IN THE UNITED STATES
NAIL PSORIASIS
REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS QUESTIONNAIRE
CHANGES IN FUNCTIONAL ABILITY AS MEASURED BY DLQI IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
QUALITY OF LIFE IMPROVEMENT AS MEASURED BY EQ-5D IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
NAIL PSORIASIS
VALIDATION OF THE ITALIAN VERSION OF THE INFANTS' DERMATITIS QUALITY OF LIFE & FAMILY DERMATITIS INDEXES
ATOPIC DERMATITIS
QUALITY OF LIFE OF PAEDIATRIC PATIENTS WITH ATOPIC ECZEMA AND THEIR FAMILIES
VALIDATION OF THE ITALIAN VERSION OF THE DERMATOLOGY LIFE QUALITY INDEX
IMPACT OF CORTICOSTEROID-SPARING EFFECT OF AN EMOLLIENT MILK ON FAMILY'S QUALITY OF LIFE OF INFANTS AFFECTED BYATOPIC DERMATITIS
SENSITIVE SKIN
FACTORS INFLUENCING QUALITY OF LIFE IN ATOPIC DERMATITIS
ATOPIC DERMATITIS
ADULTS WITH ATOPIC DERMATITIS
PREDICTORS OF STROKE RISK ASSOCIATED WITH ATRIAL FIBRILLATION
COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH
CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS WITH RECENT ISCHEMIC STROKE ORTRANSIENT ISCHEMIC ATTACK
COST-CONSEQUENCE ANALYSIS FOR THE HANDMASTER IN THE NETHERLANDS
COST AND OUTCOMES AFTER FIRST STOKE HOSPITAL ADMISSION
FACTORS RELATED TO LONGER HOSPITAL STAY AFTER FIRST-EVER ISCHEMIC STROKE
DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE APPROPRIATE STROKE PREVENTION THERAPY IN PRACTICE?
WARFARIN PATIENT SEGMENTS
MANDARIN VERSION OF STROKE IMPACT SCALE
THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE
THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE. DOES METHOD USED INFLUENCE OUTCOME?
THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE. WHICH METHOD IS MOST SUITABLE FOR HEALTHY AND COGNITIVELY IMPAIRED POPULATION?
EFFECTIVENESS OF AN EARLY REHABILITATION STRATEGY WITH HOME FOLLOW-UP FOR PATIENTS WITH ISCHEMIC VASCULAR CEREBRAL DISEASE IN MEXICO
DIABETIC PERIPHERAL NEUROPATHY
WITHDRAWN
WITHDRAWN
HEALTH CARE UTILIZATION AND EXPENDITURES ASSOCIATED WITH USE OF INSULIN GLARGINE
IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE
REDUCTION IN DIABETES DRUGS USE AND DRUG COSTS IN OBESE PEOPLE TREATED WITH ORLISTAT
THE METABOLIC EFFECTS OF ORLISTAT AND ROSIGLITAZONE ON INSULIN ACTION IN A GROUP OF CHINESE PATIENTS AFFECTED BYTHE METABOLIC SYNDROME
CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STAT IN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS
PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES
DIABETES IN GERMANY
WITHDRAWN
BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ROSIGLITAZONE IN THE TREATMENT OF TYPE-2 DIABETES. THE ITALIAN NHS PERSPECTIVE
THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS
COST OF DIABETES MELLITUS TYPE-2 AND SELF MEASUREMENT OF BLOOD GLUCOSE IN GERMANY
A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS OF CHIROPODIST CARE IN DIABETEC PATIENTS
COSTS ASSOCIATED WITH GLUCOSE CONTROL IN THE NON-DIABETIC CRITICALLY ILL PATIENT
ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND TYPE-2 DIABETES IN GERMANY AND SWEDEN
COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA
ECONOMIC EVALUATION OF SWITCHING TYPE-1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE IN A BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING
BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES
COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY IN TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN ASPART OR HUMAN SOLUBLE INSULIN-BASED BASAL/BOLUS REGIMENS IN GERMANY
ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN-INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUSTYPE-1 (DM 1) PATIENTS. COST—EFFECTIVENESS ANALYSIS
ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY
ASSESSMENT OF THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART + METFORMIN VERSUS HUMAN INSULIN + METFORMIN REGIMENS IN TYPE-2 DIABETES IN GERMANY BASED ON THE CLINICAL FINDINGS OF THE PHAZIT STUDY
FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE
COMPARATIVE EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 AND INSULIN GLARGINE IN A SUB-POPULATION OF POORLY CONTROLLED PATIENTS WITH TYPE-2 DIABETES RECEIVING ORAL ANTIDIABETIC AGENTS
COST-EFFECTIVENESS OFACARBOSE IN ADDITION TO EXISTING TREATMENTS IN TYPE-2 DIABETES IN GERMANY
COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM + HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY
HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES
COST-EFFECTIVENESS OF PREVENTIVE INTERVENTIONS IN DIABETES MELLITUS AND ITS (MACROVASCULAR)COMPLICATIONS
A LIFETIME MODELLED ECONOMIC EVALUATION COMPARING PIOGLITAZONE AND ROSIGLITAZONE FOR THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN THE UK
ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS
COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES IN A FRENCH SETTING
DIABETES PREVALENCE AND DIRECT MEDICAL COST ANALYSIS PER YEAR FROM 1997 TO 2001 IN TAIWAN
THE COST OF DIABETES MELLITUS IN SPAIN
COST OF TYPE-2 DIABETES MELLITUS IN HONG KONG CHINESE
COSTS OF STAYS OF CARDIOVASCULAR EVENTS OF DIABETIC PATIENTS IN THE FRENCH HOSPITALS
ANALYSIS OF THE COST OF DIABETES TREATMENT IN BULGARIA
EVALUATION OF THE COST-UTILITY OF INSULIN DETEMIR COMPARED TO INSULIN GLARGINE, BOTH IN COMBINATION WITH INSULIN ASPART IN TYPE-1 DIABETES IN GERMANY AND AUSTRIA
COST-UTILITY ANALYSIS IN A USA SETTING OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES
DIABETIC PERIPHERAL NEUROPATHY
IMPROVING DIABETES CARE MANAGEMENT ACROSS A SET OF COMPREHENSIVE MEASURES IN A MEDICAID MANAGED CARE ORGANIZATION
SHOULD WE LOOK FORA NEW APPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?
USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS
PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTH CARE COSTS IN U.S. PATIENTS WITH TYPE-2 DIABETES
WITHDRAWN
TYPE-2 DIABETES AND GLYCEMIC CONTROL IN GERMANY
KNOWLEDGE ABOUT INSULIN AND WILLINGNESS TO USE IT INFLUENCE GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ONLY TREATED WITH ORAL ANTIDIABETIC DRUGS—A GERMAN SURVEY
PATTERNS OF BLOOD GLUCOSE MONITORING IN RELATION TO GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE-2 DIABETES IN THE UK
MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES
EVALUATING INTERVENTIONS ALONG THE COURSE OF DISEASE
TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATES AND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL
WITHDRAWN
MEASURING QUALITY OF LIFE WITH EQ-5D IN AN AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH DIABETES MELLITUS
AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE IN TYPE-2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL
TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGY WITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES
DIABETIC PERIPHERAL NEUROPATHY
DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN
DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE BARRIER SURVEY IN PATIENTS WITH CHRONIC CONDITIONS
PERCEIVED HEALTH CARE INFORMATION ON DIABETES
TREATMENT SATISFACTION IN SUBJECTS WITH TYPE-2 DIABETES RECEIVING INSULIN GLARGINE
ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)
USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES
INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE
EVALUATION OF INCREMENTAL EFFICACY OF LATANOPROST-TIMOLOL IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE
COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)
A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE ACETATE IN WET AGE-RELATED MACULAR DEGENERATION
NUMBER OF TREATABLE EYES WITH WET SUB-FOVEAL AGE-RELATED MACULAR DEGENARATION (ARMD)
EYE ADVERSE EFFECTS ASSOCIATED WITH POLYVINYL ALCOHOL TEAR DROPS AFTER LASER ASSISTED SUBEPITHELIAL KERATECTOMY (LASEK)
COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION
COMBIGAN—COST-MINIMIZATION ANALYSIS OF BRIMONIDINE/TIMOLOL FIXED COMBINATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA
COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION
PHARMACOECONOMIC ANALYSIS OF LATANOPROST VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA IN SPAIN
COSTS AND CONSEQUENCES OF ENDOPHTHALMITIS
IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY
COST OF ENDOPHTHALMITIS
THE PREVALENCE AND COST OF TREATMENT OF PATIENTS TAKING ANTIGLAUCOMA AGENTS FOR GLAUCOMA OR OCULAR HYPERTENSION IN FRANCE
MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION
USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE QUALITY WEIGHTS WITHIN THE FRAMEWORK OF QALYS
METHODS FORA POPULATION-BASED INTERNATIONAL STUDY ON THE BURDEN OF ILLNESS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION
UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE IN THE UK
DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE PAINFUL SYMPTOM CHECKLIST ALLOWING PROVIDING A COMPLETE DESCRIPTION OF PAIN IN OPHTHALMIC DISEASES
A COMPARISON OF FREQUENTIST AND BAYESIAN STATISTICAL APPROACHES IN COST-BENEFIT ANALYSIS
IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY
ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY
ECONOMIC COMPARISON OF TWO XENETIX® 300 PRESENTATIONS
COST OF SEVERE BLUNT TRAUMA IN THE UK
PHP6 DRUG PRICE INDICES 1980-2004 IN FINLAND
MANAGING ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS
RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY
PHARMACEUTICAL CARE IN GREECE
THE IMPACT OF MEDICARE MANAGED CARE ON USE OFVA PHARMACY SERVICES
AN INTRODUCTION TO HEALTH TOURISM AND MEDICAL TOURISM
PRICING POLICIES FOR THE PHARMACEUTICAL MARKET—AN INTERNATIONAL PERSPECTIVE
MULTIPLE APPRAISAL OF DRUGS IN THE UK HEALTH CARE SYSTEM
OPPS PHARMACY HANDLING COSTS
THE CONSUMPTION OF DRUGS FINANCED BYTHE SPANISH NATIONAL HEALTH SYSTEM AND THE IMPACT OF PHARMACOVIGILANT ACTIONS
ESTIMATING THE COST SAVINGS AND RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
EFFECTS OF GENERIC SUBSTITUTION ON THE DEVELOPMENT OF PHARMACEUTICAL EXPENDITURES DURING THE PERIOD JANUARY 1998 TO MAY 2005
GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN HUNGARY
PRESCRIPTION DRUGS AND ANNUAL BENEFIT CAPS-DO PATIENTS ANTICIPATE EXCEEDING THE CAP?
GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES
PHARMACEUTICAL POLICY IN GREECE
EFFECTS OF DECENTRALIZED RESPONSIBILITY FOR COSTS OF OUTPATIENT PRESCRIPTION DRUGS ON THE PHARMACEUTICAL COST DEVELOPMENT IN SWEDEN
A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS IN THE NORDIC COUNTRIES
A SYSTEMATIC REVIEW OF THE EUROPEAN PHARMACEUTICAL MARKET AND THE IMPACT OF EUROPEAN UNION REGULATION AND JURISDICTION
USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS
ADHERENCE INDEX OF PERFORMANCE—A NEW METHOD AND TOOL FOR ONGOING EVALUATION OF MEDICATION ADHERENCE IMPROVEMENT INITIATIVES
PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)
ECONOMIC EVALUATION OF NEWTECHNOLOGIES IN THE HOSPITAL SETTING
REIMBURSEMENT OF HIGH-PRICED NEW EMERGING MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL CARE SYSTEM
PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM IN SAUDI ARABIA
CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002
COMBINING PHARMACY AND HOSPITAL DATA IN A RISK ADJUSTMENT MODEL
USE OF PHARMACOECONOMICS FOR CREATION OF THE STATE FORMULARY IN UKRAINE
EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE
AGE AND GENDER IN PHARMACEUTICAL EXPENDITURE
WITHDRAWN
PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS
BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY EMPLOYEES
PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES
THE IMPACT ON DECISION-MAKING OF CHANGING COST-EFFECTIVENESS OF HEALTH TECHNOLOGIES OVERTIME
EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES IN SWEDEN AND FINLAND—A CROSS COUNTRY COMPARISON
PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD
IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS
COST AVOIDANCE OF CLINICAL PHARMACIST INTERVENTIONS AT A UNIVERSITYTEACHING HOSPITAL
APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) PRIMARY CARE CENTRES IN THE PARISIAN REGION
DEFINING COMPLIANCE/ADHERENCE AND PERSISTENCE
EVALUATION OF THE RELATIONSHIP BETWEEN PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED QUALITY OF LIFE USING WHOLESALE ACQUSITION COST AND AVERAGE EFFECT SIZE
A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING
COST EFFECTIVENESS OF ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)
WITHDRAWN
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GROWN-UPS
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
THE BAD STUDY
THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
STIMULANT MEDICATION TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IS ASSOCIATED WITH DECREASED EMERGENCY DEPARTMENT COSTS AND UTILIZATION
A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS
WITHDRAWN
THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
GALANTAMINE REDUCES CAREGIVER BURDEN
EFFECT OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) ON COST OF CARE IN THE CANADIAN OUTCOMES STUDY IN DEMENTIA
HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS
TRANSLATION, GREEK ADAPTATION AND STANDARDIZATION OF THE VERONA SERVICE SATISFACTION SCALE (VSSS-54)
CHANGES IN NOVEL ANTIPSYCHOTIC USE IN ELDERLY INPATIENTS
RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS
TREATMENT PERSISTENCE
HOSPITALIZATIONAND MEDICATION USE IN SCHIZOPHRENIA PATIENTS RECEIVING RISPERIDONE LONG-ACTING INJECTABLE OR ORAL ATYPICAL ANTIPSYCHOTIC MEDICATION
IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATIONAND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA
GEO OBSERVATIONAL STUDY
EFFECTIVENESS AND TOLERABILITY OUTCOMES OF RISPERIDONE LONG-ACTING INJECTION COMPARED TO CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE CANADIAN PSYCHIATRIC HOSPITAL
USING CLAIMS DATA TO ESTIMATE THE ANNUAL PREVALENCE OF SCHIZOPHRENIA IN THE UNITED STATES, 2002
12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS NO TREATMENT FOR SCHIZOPHRENIA RELAPSE PREVENTION
DRUG UTILIZATION PATTERNS AND COSTS AND TOTAL COSTS OF SCHIZOPHRENIA TREATMENT IN AN INSURED POPULATION
FACTORS AFFECTING COST OF SCHIZOPHRENIA TREATMENT WITH ATYPICAL ANTIPSYCHOTIC AGENTS
12 MONTH COST-UTILITY ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
NEUROLEPTIC TREATMENT OF SCHIZOPHRENIA IN AMBULATORY CARE IN GERMANY
FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
LONG-TERM TREATMENT OF SCHIZOPHRENIA FOR RELAPSE PREVENTION (LASER)
ARE INDIRECT COSTS MEASUREMENTS RELEVANT IN A SCHIZOPHRENIC PATIENTS POPULATION? AN OVERVIEW OF A LONGITUDINAL STUDY IN FRANCE
CASE STUDY OF PATTERN MIXTURE APPROACH FOR COMBINING COMPLETION RATES AND EFFICACY FOR CLINCALLY MEANINGFULL OUTCOMES IN SCHIZOPHRENIA DRUG TRIALS
THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN THE UNITED STATES IN 2002
A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA
ARE QALYS SUITABLE FOR SCHIZOPHRENIA TRIALS?
LONG-TERM MAINTENANCE OF INITIAL HEALTH RELATED QUALITY OF LIFE (HRQL) IMPROVEMENTS GAINED THROUGH ANTIPSYCHOTIC TREATMENT
REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS)
COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE
CLINICAL COMPARISON OF SSRIS AND SNRIS IN MAJOR DEPRESSIVE DISORDER
DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD
COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
COST OF AFFECTIVE DISORDERS IN EUROPE
QUALITY OF LIFE IN MAJOR DEPRESSION
QUALITY OF LIFE IN MAJOR DEPRESSION
DEVELOPMENT OF A COMPREHENSIVE EMOTIONAL, SOMATIC AND PAINFUL PHYSICAL SYMPTOMS CHECKLIST IN DEPRESSION IN FIVE EUROPEAN COUNTRIES
CLINICAL AND TREATMENT FACTORS INFLUENCING THE OUTCOME OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS
PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION
COST ANALYSIS OF FOURTREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS
PHARMACOECONOMIC EVALUATION OFTIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
ECONOMIC EVALUATION OF TIOTROPIUM AND SALMETEROL IN THE TREATMENT OF COPD IN GREECE
COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND
COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND
COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND
PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS
MANAGEMENT OF COPD IN BELGIUM
THE BURDEN OF LUNG DISEASE (BOLD) ECONOMIC MODEL
COST ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION DURING TREATMENT FOR RESPIRATORY TRACK INFECTIONS (RTIS)WITHTELITHROMYCIN OR CLARITHROMYCIN OR AMOXICILLIN/CLAVULANIC ACID IN GREECE
HEALTH CARE RESOURCES UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THEIR SEVERITY IN SPAIN
OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
QUALITY OF LIFE IN COPD
DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BYTHE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?
IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS—DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS
PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS—SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q
PATIENT SATISFACTION WITH TREATMENT FOR COPD
THE SOCIETAL COST OF AUTOLOGOUS, ALLOGENEIC AND PERIOPERATIVE RBC TRANSFUSION—THE CASE OF SWEDEN
COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO
THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY
TOTAL INSURANCE COST OF TREATMENT OF HIP FRACTURES ACCORDING TO THE LOAD STABILITY OF DIFFERENT SURGICAL METHODS
FACTORS ASSOCIATED WITH BLOOD TRANSFUSION COSTS DURING AND FOLLOWING SPINAL SURGERY IN THE UNITED STATES
DIFFERENCES IN BLOOD TRANSFUSION COSTS BY HIP AND KNEE REPLACEMENT AND REVISION SURGERY SUBTYPES
“TECHNO-MARKERS” FOR THE ASSESSMENT OF HEALTH TECHNOLOGY UTILIZATION
APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS)TO MONITOR QUALITYANDTO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER—AN EXAMPLE OF MEETING ISO 9001
DISCLOSURE INFORMATION
Erratum